Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
02:13a VOLKSWAGEN : aligns MAN, Scania truck brands in new holding
02:13a GOLAR LNG USA : Ophir Energy plc appoints Golar as Midstream Partner for Fortuna FLNG Project in Equatorial Guinea
02:11a TATA MOTORS : Targets Uganda Mining Sector With Prima Launch
02:08a TETHYS OIL : First quarter report 2015
02:08a TELEFONICA DEUTSCHLAND : DGAP-News: Telefónica Deutschland Holding AG: Telefónica Deutschland delivers on key integration milestones with a strong financial performance
02:08a EMOA : 150428 – Emotra – PM – AGM bulletin
02:08a DEUTSCHE LUFTHANSA : Lufthansa increases first quarter result
02:08a OIL BASINS : Section 708A Cleansing Notice
02:08a CHAGALA : Dividend announcement
02:08a INNOLUX : Announces Unaudited 2015 First Quarter Net Income NT$8.65 Billion and EPS NT$0.87
Latest news
Advertisement
Hot News 
LLOYDS BANKING : *traders: jefferies raises lloyds to 'buy' ('hold')
Novel Gene-Based Therapy for Achromatopsia Demonstrates Functional Rescue of Cone Cells
DBV TECHNOLOGIES : to Present at Upcoming Investor Conferences
PATTERSON : Acquiring Animal Health International will more than double the size of Patterson’s veterinary business.
INVENSENSE : meets 4Q profit forecasts
Most Read News
05/04 WASION : Announcements and Notices - Placing of Existing Shares and Subscription for New Shares
05/04DJAsia Shares Mixed as Australia Awaits Rate Decision
05/04 CANFOR PULP PRODUCTS : Announces Voting Results for the Election of Directors
05/04DJFACEBOOK : Investor Urges Facebook to Eliminate Supervoting Stock
05/04 COCA COLA : NMSU FOOTBALL: Allen Theatres to fund football lockerroom renovations
Most recommended articles
02:06aDJGermany's Metro's Net Loss Widens
02:06aDJDEUTSCHE LUFTHANSA : Lufthansa Swings to Net Profit in 1st Quarter
02:04aDJAdidas Net Profit Up 8.2% in First Quarter
02:01a Shanghai bans leaders' family members from business
01:53a Australia's RBA cuts rates, markets wonder if that's all
Dynamic quotes  
ON
| OFF